|
|
Article: Positive Outcome of Phase I DNA Influenza Study; PowderMed Announces First Clinical Trial Results.
- Article from:
- PR Newswire
- Article date:
- November 18, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
OXFORD, England, November 18 /PRNewswire/ -- PowderMed Ltd (PowderMed), a company focusing on the development of therapeutic DNA vaccines has announced positive results in a Phase I clinical trial of a proprietary prophylactic DNA influenza vaccine.
The trial examined three doses of the DNA influenza vaccine (1, 2 and 4 micrograms), in 12 volunteers per arm, making 36 volunteers in total. Each was administered as a single dose to healthy adult volunteers. The immune response was assessed according to the criteria laid down by the Committee for Proprietary Medicinal Products (CPMP) for the approval of annual flu vaccines in the European Union. All three doses ...